Skip to content

Alkermes ALKS EV / sales

EV / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
3.3×-0.1×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
3.7×+1.0×
AbbVie logo
AbbVieABBV
7.5×+1.0×
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
12.1×-0.9×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.4×

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

Based on the most recent quarter.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's EV / sales?
Alkermes (ALKS) reported EV / sales of 4.6× in Q1 2026.
How has Alkermes's EV / sales changed year-over-year?
Alkermes's EV / sales increased by 36.8% year-over-year, from 3.3× to 4.6×.
What is the long-term trend for Alkermes's EV / sales?
Over 5 years (2020 to 2025), Alkermes's EV / sales has grown at a -2.1% compound annual growth rate (CAGR), from 3.2× to 2.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.